Metabolic Dysfunction-Associated Steatohepatitis in Focus: Pathogenesis, Non-Invasive Diagnostics, and Future...

Area of Science:

• Hepatology and metabolic disease research.
• Development of advanced diagnostic tools for liver conditions.

Background:

• Metabolic dysfunction-associated steatohepatitis (MASH) is the advanced stage of metabolic dysfunction-associated steatotic liver disease (MASLD).
• MASH is linked to obesity, insulin resistance, and metabolic syndrome, posing a significant global health challenge.
• Current diagnostic methods, including liver biopsy, have limitations, necessitating alternative approaches.

Purpose of the Study:

• To review the current understanding of MASH pathophysiology.
• To explore diagnostic challenges and innovative non-invasive strategies for MASH detection and fibrosis evaluation.
• To highlight the importance of updated criteria and multi-omics approaches for risk stratification.

Main Methods:

• Review of current literature on MASH pathophysiology and diagnostics.
• Evaluation of non-invasive diagnostic techniques such as elastography, MRI, and serum biomarkers (e.g., cytokeratin-18, NIS4, FAST scores).
• Discussion of updated MASLD criteria for improved risk stratification.

Main Results:

• Non-invasive techniques show promise for detecting MASH and assessing fibrosis severity.
• Updated MASLD criteria enhance risk stratification, including lean MASH phenotypes.
• Multi-omics approaches are crucial for future personalized MASH management.

Conclusions:

• Advancing non-invasive diagnostics is essential for managing the growing burden of MASH.
• Personalized strategies are needed for early detection, disease halting, and improved patient outcomes.
• Integrating multi-omics data will refine understanding and treatment of MASH.